Slide 1: Intimation of Investor Presentation Q4 FY 2024-25
Date: 29th May, 2025 To, To, The Manager (Listing) Listing Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot No. C/1, G Block, Dalal Street, Fort, Mumbai - 400 001 Bandra-Kurla Complex, Bandra (E), Mumbai – 400051 BSE Scrip Cod
Slide 2: Anuh Pharma Ltd. Investor Presentation FY2025
ANUH PHARMA LTD. Investor Presentation FY2025 (May‐25) BSE Scrip Code: 506260 Bloomberg Code: ANUH IN Reuters Code: ANUH.BO www.anuhpharma.com 1
Slide 3: Safe Harbor Statement
Safe Harbor Statement This presentation may include certain “forward looking statements”, based on current expectations, within the meaning of applicable laws and regulations. Actual results may differ and the Company does not guarantee realization of these statements. The Company also disclaims any
Slide 4: Table of content
Table of content 01 FY 2025 & FY 2024 HIGHLIGHTS 02 COMPANY OVERVIEW 03 INFRASTRUCTURE 04 FUTURE OUTLOOK 05 CORPORATE SOCIAL RESPONSIBILITY ANUH PHARMA LTD.
Slide 5: FY 2025 & FY 2024 Highlights
01 FY 2025 & FY 2024 HIGHLIGHTS
Slide 6: Message from Joint MD
Message from Joint MD Dear Valued investors and shareholders, I am pleased to present the Investor Presentation for the fourth quarter and financial year ending 2024–25. This year’s results clearly show the strength of our diversified product portfolio, driven by continuous innovation. They also ref
Slide 7: Message from Joint MD
Message from Joint MD Business highlights: In FY25, Anuh Pharma’s overall customer base increased from 698 to 737, indicating a notable expansion in market reach. Notably, the export customer base grew from 260 to 304, reflecting strong diversification and deeper penetration into international marke
Slide 8: Financial performance highlights (last 5 years)
Financial performance highlights (last 5 years) Total Revenue (INR in Cr.) EBITDA (INR in Cr.) 659 671 87 537 70 492 443 55 57 52 20‐21 21‐22 22‐23 23‐24 24‐25 20‐21 21‐22 22‐23 23‐24 24‐25 PBT (INR in Cr.) PAT (INR in Cr.) 78 60 61 47 47 39 39 36 28 31 20‐21 21‐22 22‐23 23‐24 24‐25 7
Slide 9: Business mix revenue contribution
Business mix revenue contribution Revenue Split (Rs. In Cr.) Top 5 customers contribution 33% 662 647 31% 31% 31% 30% 343 363 298 304 29% Domestic Export Total FY 25 FY 24 FY 25 FY 24 Export Sales Domestic Sales Total Sales GEOGRAPHICAL EXPORT SALES FY 2025 GEOGRAPHICAL EXPORT SALES FY 2024 LATIN LA
Slide 10: Product mix revenue contribution
Product mix revenue contribution 221 FY 24 FY 25 (INR in Cr.) 207 113 96 102 96 90 67 37 38 40 34 33 34 31 28 20 20 Erythromycin Higher Chloramhenicol Pyrazinamide Sulphadoxine Cortico Ambroxol HCL Gliclazide Other Items Macrolides Steroids 9
Slide 11: Track Record
Track Record EBITDA Margin % Net Profit Margin % 13.48 9.30 12.76 10.69 10.89 10.64 6.86 7.16 6.58 6.28 20‐21 21‐22 22‐23 23‐24 24‐25 20‐21 21‐22 22‐23 23‐24 24‐25 ROE (%) ROCE (%) 23 26.82 16 15 16 15 19.54 18.58 19.85 18.85 20‐21 21‐22 22‐23 23‐24 24‐25 20‐21 21‐22 22‐23 23‐24 24‐25 10
Slide 12: Track Record
Track Record Outflow of Dividend (INR in Cr.) Current ratio 15 2.20 2.11 13 1.98 1.91 10 1.70 9 8 20‐21 21‐22 22‐23 23‐24 24‐25 # # Recommended by BOD, subject to members' approval 20‐21 21‐22 22‐23 23‐24 24‐25 Debt to Equity Net Working Capital (Days) 0.07 72 58 56 61 35 0.03 0.01 0.01 ‐ 20‐21 21‐2
Slide 13: FY 25 and FY 24 Financial Performance
FY 25 and FY 24 Financial Performance Rs. In Cr. 3 months 3 months Variance 12 months 12 months Variance Financial Highlights ended ended (%) ended ended (%) 31/03/2025 31/12/2024 QoQ 31/03/2025 31/03/2024 YoY Operating Revenue 198.14 159.51 24.22 661.51 647.00 2.24 Operating Profit 44.20 34.16 29.4
Slide 14: Company Overview
02 COMPANY OVERVIEW
Slide 15: Company Overview
Company Overview The Company derived ~55% of its revenues from exports in FY24‐25. The Company has strong marketing partnerships with 360 customers in over 59 countries including Europe, Mexico and South Africa. The expansion project with state of the art manufacturing facility targeted at regulated
Slide 16: Journey So Far…
Journey So Far… Year Achievements 1989 Started manufacturing Erythromycin salts with capacity of 150 MTPA , followed by doubling the capacity to 300 MTPA in 1995. 2002 Received WHO‐GMP for its facilities. 2006 Doubled the capacity by acquiring new plot of 1800 SQMT to expand the output capacity 600
Slide 17: Journey So Far…
Journey So Far… Year Achievements Received EU GMP for Erythromycin, Erythromycin ethyl succinate, Pyrazinamide, Pyrimethmine and Sulphadoxine from 2019 AEMPS Spain. 2019 Enhanced the capacity by acquiring new plot of 7800 SQMT to expand the output capacity by 600 MTPA. 2019 USFDA inspection passed s
Slide 18: Competitive Advantage
Competitive Advantage Market leadership: Erythromycin salts Competitive Advantage Pyrazinamide • Regulatory approvals • Environmental health and Safety Compliance (Audited an Sulfadoxine approved by Multinational companies). Ambroxol HCL • Well diversified sourcing with backward integration in key p
Slide 19: Product List
Product List Macrolides Higher Macrloides Anti Asthamatics 1. Erythromycin 11,12 Carbonate 1. Azithromycin 1. Acebrophylline 2. Erythromycin Base Anti TB Anti Diabetic 3. Erythromycin Estolate 1. Pyrazinamide 1. Gliclazide 4. Erythromycin Propionate 2. Isoniazid 2. Vildagliptin 5. Erythromycin Ethyl
Slide 20: Product List
Product List Corticosteroids 1. Beclomethasone Dipropionate 11. Prednisolone Acetate 2. Betamethasone Acetate 12. Prednisolone Sodium Phosphate 3. Betamethasone Dipropionate 13. Triamcinolone Acetonide 4. Betamethasone Sodium Phosphate 14. Triamcinolone Base 5. Betamethasone Valerate 15. Methyl Pred
Slide 21: Key Management Personnel & Senior Management
Key Management Personnel & Senior Management VC VICE CHAIRMAN MR. BIPIN SHAH JMD JMD JOINT JOINT MANAGING MANAGING DIRECTOR DIRECTOR MR. RITESH SHAH MR. VIVEK SHAH VP CS & VP MARKETING CFO COMPLIANCE R&D QUALITY OPERATION QUALITY OFFICER MR. RAJU MR. DARSHAN MR. MANAN DR. SANJAY MR. SANJAY MR. GULSH
Slide 22: Key Management Personnel & Senior Management
Key Management Personnel & Senior Management Name Designation Profile Mr. Arun Todarwal Chairman Fellow member of the ICAI and having practice since 1981. He has handled various professional assignments in India and abroad including Audits, Taxation, International Taxation, Joint Ventures, Due Dilig
Slide 23: Latest Shareholding Pattern
Latest Shareholding Pattern Public 30.08 % Promoter & Promoter Group, 69.92 % Market capitalization INR 1,039 Cr. (As on 23rd May, 2025) Free float market capitalization INR 313 Cr. (As on 23rd May, 2025) 22
Slide 24: Infrastructure
03 INFRASTRUCTURE
Slide 25: State of Art manufacturing facility
State of Art manufacturing facility • Anuh Pharma has a EUGMP/ WHO Pre qualified approved manufacturing facility at Tarapur spread across 11,400 sq. meters with 8 API’s blocks and 1 intermediate block with total capacity of 2200 MTPA – this includes new expanded capacity. • With commissioning of Zer
Slide 26: Manufacturing facility Photos
Manufacturing facility Photos
Slide 27: Manufacturing facility Photos
Manufacturing facility Photos
Slide 28: Manufacturing facility Photos
Manufacturing facility Photos
Slide 29: Manufacturing facility Photos
Manufacturing facility Photos
Slide 30: Manufacturing facility Photos
Manufacturing facility Photos
Slide 31: Other Facilitates
Other Facilitates The entire facility is equipped with latest Fire Fighting and Safety Measures. Zero Liquid Discharge Effluent Control system for treating 100% of Generated Pollution. 100% Power Backup via dedicated power line from Power Distributor to our premises. Adjoining office and a Training
Slide 32: Dedicated Research & Development Facility
Dedicated Research & Development Facility FACILITATE ACTIVITIES LAB SCALE REACTION THAT LEAD TO DEVELOP PROCESSES AND BATCHES TO VALIDATE CHARACTERIZATION AND PRODUCTS. RESEARCH PROFILING OF PRODUCTS. ANALYTICAL DEV CHEMICAL SYNTHESIS PILOT PLANT IN HOUSE R&D LAB APL NEW PRODUCTS & PROCESSES A dedic
Slide 33: Future Outlook
04 FUTURE OUTLOOK
Slide 34: Future Outlook – Growth Strategy
Future Outlook – Growth Strategy Moving forward, Anuh Pharma’s growth strategy relies on market expansion, the addition of new products, and inorganic growth opportunities. The future of Active Pharmaceutical Ingredients (API) lies in innovation and the development of complex chemistry products, wit
Slide 35: Future Outlook – Product under development
Future Outlook – Product under development Sr. No Product Name Therapeutic application 1) Ticagrelor Anti Platelet 2) Linagliptin Anti Diabetic 3) Empagliflozin Anti Diabetic 4) Bilastine HCl Anti‐Histamine 5) Pyronaridine Anti‐Malarial Tetraphosphate 6) Vonoprazon Anti‐Ulcerative Fumarate 7) Ethamb
Slide 36: Corporate Social Responsibility
05 CORPORATE SOCIAL RESPONSIBILITY
Slide 37: CSR …. Servicing Society for better tomorrow
CSR …. Servicing Society for better tomorrow • APL takes corporate sustainability and social responsibility as a voluntary commitment rather than an obligation. We engage in social activities encompassing education, healthcare, sanitation, vocational skill building, rural development & natural conse
Slide 38: Thank You
Thank You For specific queries please feel free to contact; Mr. Darshan Rampariya (CFO) darshan.r@anuhpharma.com